Search

• A cocktail of chitinolytic enzymes was developed to efficiently produce GlcNAc from chitin. • An efficient and green extraction-pretreatment integrated process was established using deep eutectic solvent (DES). • The chitin extraction process from chitinous wastes using DES was proved as an universal and reusable approach. • Chitin pretreated by DES exhibited 2–6-fold hydrolysis efficiency better than raw chitinous wastes. In this study, we present an efficient and green extraction-pretreatment integrated approach for enhancing enzymatic conversion of chitinous wastes into N -acetyl- d -glucosamine (GlcNAc). Firstly, the enzyme cocktail containing a chitinase Cm Chi1 and a N-acetyl glucosaminase Cm NAGase were constructed for hydrolyzing chitin into sole GlcNAc. Secondly, deep eutectic solvent (DES), consisting of choline chloride and glycollic acid was used to treat chitinous wastes. Under optimal conditions, chitin yield reach to 72 % with a purity of 98 %. Fourier-transform infrared spectroscopy, thermogravimetric analysis, and X-ray diffraction analysis revealed that the crystallinity and thermal stability of the obtained chitin decreased upon DES treatment without alteration of the chemical structure or deacetylation. Finally, the concentration of GlcNAc was increased 2–6 folds by enzymatic hydrolysis of DES-treated chitinous wastes (including shrimp shell, crab shell, ganoderma spores wall, and mycelium). The process provides a promising strategy for degrading chitinous wastes to produce high valued GlcNAc. [Display omitted] [ABSTRACT FROM AUTHOR]

Alzheimer’s disease (AD) is characterized by amyloid β (Aβ) peptide aggregation and cholinergic neurodegeneration. Therefore, in this paper, we examined silibinin, a flavonoid extracted from Silybum marianum , to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Aβ peptide aggregation for AD treatment. To achieve this, we used molecular docking and molecular dynamics simulations to examine the affinity of silibinin with Aβ and AChE in silico. Next, we used circular dichroism and transmission electron microscopy to study the anti-Aβ aggregation capability of silibinin in vitro. Moreover, a Morris Water Maze test, enzyme-linked immunosorbent assay, immunohistochemistry, 5-bromo-2-deoxyuridine double labeling, and a gene gun experiment were performed on silibinin-treated APP/PS1 transgenic mice. In molecular dynamics simulations, silibinin interacted with Aβ and AChE to form different stable complexes. After the administration of silibinin, AChE activity and Aβ aggregations were down-regulated, and the quantity of AChE also decreased. In addition, silibinin-treated APP/PS1 transgenic mice had greater scores in the Morris Water Maze. Moreover, silibinin could increase the number of newly generated microglia, astrocytes, neurons, and neuronal precursor cells. Taken together, these data suggest that silibinin could act as a dual inhibitor of AChE and Aβ peptide aggregation, therefore suggesting a therapeutic strategy for AD treatment. [ABSTRACT FROM AUTHOR]